Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials

References

• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DPM, Griffiths CEM, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377-85
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64
   PubMed Web of Science ®Google Scholar
• Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-912
   PubMed Web of Science ®Google Scholar
• Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl II):ii65-8
   PubMedGoogle Scholar
• Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50(6):859-66
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Li Wan Po A, Williams HC, et al. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999;141:185-91
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34:1167-70
   PubMed Web of Science ®Google Scholar
• Mease PJ. Measures of psoriatic arthritis. Arthritis Care Res 2011;63(11):S64-85
   Google Scholar
• Mease PJ, Antoni CE, Gladman DD, et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl II):ii49-54
   PubMedGoogle Scholar
• Brazier J, Ratcliffe J, Salomon JA, et al. Measuring and valuing health benefits for economic evaluation. Oxford University Press Inc; NY, USA: 2007
   Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford University Press Inc; NY, USA: 1996
   Google Scholar
• Blome C, Beikert FC, Rustenbach SJ, et al. Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Arch Dermatol Res 2013;305:197-204
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med 2005;353:1516-22
   PubMed Web of Science ®Google Scholar
• Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA 2007;298:221-4
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Armstrong AW. Psoriasis outcome measures: a report of the GRAPPA 2012 annual meeting. J Rheumatol 2013;40:1428-33
   PubMed Web of Science ®Google Scholar
• Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12
   PubMed Web of Science ®Google Scholar
• Bagel J, Lynde C, Tyring S, et al. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol 2012;67:86-92
   PubMed Web of Science ®Google Scholar
• Brunasso AMG, Salvini C, Massone C. Efalizumab for severe palmoplantar psoriasis: an open-label pilot trial in five patients. J Eur Acad Dermatol Venerol 2009;23:415-19
   PubMedGoogle Scholar
• Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2012;66:369-75
   PubMed Web of Science ®Google Scholar
• Berth-Jones J, Thompson J, Papp K. A study examining the inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. Br J Dermatol 2008;159:407-12
   PubMedGoogle Scholar
• Brunasso AMG, Salvini C, Massone C. Efalizumab for severe palmoplantar psoriasis: an open-label pilot trial in five patients. J Eur Acad Dermatol Venerol 2009;23:415-19
   PubMedGoogle Scholar
• Bushnell DM, Martin ML, McCarrier K, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermtolog Treat 2012;24(5):356-60
   PubMedGoogle Scholar
• Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatologic perspective. J Am Acad Dermatol 2006;54:685-704
   PubMed Web of Science ®Google Scholar
• Basra MK, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008;159:997-1035
   PubMed Web of Science ®Google Scholar
• Evers AWM, Duller P, van de Kerkhof PCM, et al. The impact of chronic skin disease on daily life (ISDL): a generic and dermatology-specific health instrument. Br J Dermatol 2008;158:101-8
   PubMed Web of Science ®Google Scholar
• Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumaol 2003;30:167-78
   PubMed Web of Science ®Google Scholar
• Linder D, Sampogna F, Torreggiani A, et al. Psodisk, a new visual method for assessing the burden of psoriasis on patients. J Eur Acad Dermatol Venereol 2012;26(9):1163-6
   PubMed Web of Science ®Google Scholar
• Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2012;24(Suppl 2):17-22
   Google Scholar
• Grozdev I, Kast D, Cao L, et al. Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool. J Investig Dermatol 2012;132:1111-16
   PubMed Web of Science ®Google Scholar
• Strand V, Sharp V, Koenig AS, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012;71(7):1143-50
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35
   PubMed Web of Science ®Google Scholar
• Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20
   PubMed Web of Science ®Google Scholar
• van Gestel AM, Prevoo MLL, van’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40
   PubMed Web of Science ®Google Scholar
• Gladman DD, Tom BD, Mease PJ, Farewell VT. Informing response criteria for psoriatic arthritis. I. Discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. J Rheumatol 2010;37:1892-7
   PubMedGoogle Scholar
• Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441-7
   PubMed Web of Science ®Google Scholar
• Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2010;70:272-7
   PubMedGoogle Scholar
• Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986-91
   PubMed Web of Science ®Google Scholar
• Helliwell PS, Firth J, Ibrahim GH, et al. Development of an assessment tool for dactylitis in psoriatic arthritis. J Rheumatol 2005;32:1745-50
   PubMed Web of Science ®Google Scholar
• Mander M, Simpson JM, McLellan A, et al. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987;46:197-202
   PubMed Web of Science ®Google Scholar
• Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127-32
   PubMed Web of Science ®Google Scholar
• Gladman DD, Cook RJ, Schentag C, et al. The clinical assessment of patients with psoriatic arthritis: results of a validation study of the SpondyloArthritis Research Consortium of Canada (SPARCC). J Rheumatol 2004;31:1126-31
   PubMed Web of Science ®Google Scholar
• Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686-91
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91
   PubMed Web of Science ®Google Scholar
• Leung YY, Png ME, Wee HL, Thumboo J. Comparison of EuroQol-5D and Short-Form-6D utility scores in multiethnic Asian patients with psoriatic arthritis: a cross-sectional study. J Rheumatol 2013;40:459-65
   Google Scholar
• Fayers PM, Machin D. Quality of life: the assessment, analysis and interpretation of patient-reported outcomes. 2nd edition. John Wiley & Sons, Ltd, West Sussex, England; 2007
   Google Scholar
• Lloyd A, Reeves P, Conway P, et al. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Br J Dermatol 2009;160:380-6
   PubMed Web of Science ®Google Scholar
• Knight C, Mauskopf J, Singh A, et al. Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. Eur J Health Econ 2012;13:145-56
   PubMed Web of Science ®Google Scholar
• Villacorta R, Hay J, Messali A. Cost effectiveness of moderate to severe psoriasis treatment with etanercept or ustekinumab in the United States. Pharmacoeconomics 2013;31(9):823-39
   PubMed Web of Science ®Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10(46):1-233; i–iv
   PubMed Web of Science ®Google Scholar
• Pan F, Brazier N, Shear N, et al. Cost utility analysis based on a head-to-head phase 3 clinical trial comparing ustekinumab and etanercept in patients with moderate to severe plaque psoriasis: a Canadian perspective. Value Health 2011;14:652-6
   PubMedGoogle Scholar
• Bojke L, Epstein D, Craig D, et al. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology 2011;50:iv39-47
   PubMed Web of Science ®Google Scholar
• Cummins E, Asseburg C, Prasad M, et al. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ 2012;13:801-9
   PubMed Web of Science ®Google Scholar
• Cummins E, Asseburg C, Punekar YS, et al. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value Health 2011;14:15-23
   PubMed Web of Science ®Google Scholar
• Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15(10):1-323.i-xvii
   PubMedGoogle Scholar
• Bansback NJ, Ara R, Barkham N, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology 2006;45:1029-38
   PubMedGoogle Scholar
• Longworth L, Rowen D. NICE DSU technical support document 10: the use of mapping methods to estimate health state utility values. Report by the Decision Support Unit; 2011. p. 1-31
   Google Scholar
• Anis AH, Bansback N, Sizto S, et al. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat 2011;22:65-74
   PubMed Web of Science ®Google Scholar
• Sizto S, Bansback N, Feldman SR, et al. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 2009;160:1264-72
   PubMed Web of Science ®Google Scholar
• Olivieri I, de Portu S, Salvarani C, et al. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology 2008;47:1664-70
   PubMed Web of Science ®Google Scholar
• Affleck AG, Bottomly JM, Auland M, et al. Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scale psoriasis in Scotland. Curr Med Res Opin 2011;27(1):269-84
   PubMed Web of Science ®Google Scholar
• Schmitt J, Meurer M, Klon M, et al. Assessment of health states utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol 2008;158:351-9
   PubMed Web of Science ®Google Scholar
• Zug KA, Littenberg B, Baughman RD, et al. Assessing the preferences of patients with psoriasis. A quantitative, utility approach. Arch Dermatol 1995;131:561-8
   PubMedGoogle Scholar
• Khanna D, Frech T, Khanna PP, et al. Valuation of scleroderma and psoriatic arthritis health states by the general public. Health Qual Life Outcomes 2010;8:112
   PubMedGoogle Scholar
• Duffin KC, Gottlieb AB. Outcome measures for psoriasis severity: a report from the GRAPPA 2012 annual meeting. J Rheumatol 2013;40:1423-4
   PubMed Web of Science ®Google Scholar
• Pathirana D, Ormerod AD, Saiag P, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(Suppl 2):5-70
   Google Scholar
• Basch E. Beyond the FDA PRO Guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health 2012;15:401-3
   PubMed Web of Science ®Google Scholar
• Ryan C, Korman NJ, Gelfand JM, et al. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol 2014;70(1):146-67
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Healy P, et al. Outcome measures in psoriatic arthritis. J Rheumatol 2007;34:1159-66
   PubMed Web of Science ®Google Scholar
• Adams R, Walsh C, Veale D, et al. Understanding the relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in inflammatory arthritis. Pharmacoeconomics 2010;28(6):477-87
   PubMedGoogle Scholar
• Coates LC, Mumtaz A, Helliwell PS, et al. Development of a disease severity and responder index for psoriatic arthritis (PsA) – Report of the OMERACT 10 PsA special interest group. J Rheumatol 2011;38:1496-501
   PubMedGoogle Scholar
• Dolan P. The measurement of health related quality of life for use in resource allocation decisions in health care. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics. Elsevier Science BV; Amsterdam, The Netherlands: 2000. p. 1723-60
   Google Scholar
• McCabe C, Edlin R, Meads D, et al. Constructing indirect utility models: some observations on the principles and practice of mapping to obtain health state utilities. Pharmacoeconomics 2013;31:635-41
   PubMedGoogle Scholar
• Brazier J, Akerhurst R, Brennan A, et al. Should patients have a greater role in valuing health states? Appl health Econ Health Policy 2005;4(4):201-8
   PubMedGoogle Scholar
• Currie C, Conway P. Evaluation of the association between EQ5D utility and dermatology life quality index (DLQI) score in patients with psoriasis. Value Health 2007;10(6):A470-1
   Google Scholar
• Basra MK, Pereira F, Finlay AY, et al. EuroQol-5D (EQ-5D): its use in pharmacoeconomics studies in dermatology. Abstract 402 J Investig Dermatol 2012;132(S2):S72
   Google Scholar
• Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Analysis of three outcomes measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol 2012;166(4):797-802
   PubMed Web of Science ®Google Scholar
• Krueger GG, Feldman SR, Camisa C, et al. Position paper. Two considerations for patients with psoriasis: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-5
   PubMed Web of Science ®Google Scholar
• Basra MK, Cruz P, Finlay AY, et al. The Dermatology Life Quality Index (DLQI) and EuroQol-5D (EQ-5D): is there a correlation between these instruments? [Abstract 401] J Investig Dermatol 2012;132(S2):S72
   Google Scholar
• Armstrong AW, Duffin KC, Garg A, et al. Exploring priority research areas in psoriasis and psoriatic arthritis from dermatologists’ perspective: a report from the GRAPPA 2011 annual meeting. J Rheumatol 2012;39:2204-10
   PubMedGoogle Scholar